


2018



Progetto Ematologia Romagna

Meccanismo oncogenetico dell'inflammatione


Giovanni Barosi – Fondazione IRCCS Policlinico S. Matteo,
Pavia



2018

Inflammation

Protective response of the organism to stimulation by invading pathogens or endogenous signals such as damaged cells, thus resulting in the elimination of the initial cause of injury, the clearance of necrotic cells and tissue repair




PAMPS (pathogen-associated molecular patterns):

- ✓ cell wall components (LPS, β -glucan)
- ✓ flagellar components (flagellin)


DAMPs (danger-associated molecular patterns)

- ✓ Nuclear proteins (HMGB1), histones
- ✓ Purine metabolites such as ATP
- ✓ Uric acid
- ✓ Mitochondrial components (formyl peptides, mitochondrial DNA)




Germline-encoded pattern-recognition receptor (PRR)

TLR = Toll-like receptor
AP-1 = Activator protein-1



Inflammasome



2018

Inflammation key elements

Chemical mediators

- ✓ Cytokine
- ✓ Chemokines
- ✓ Growth factors


Cells

- ✓ Macrophages
- ✓ Neutrophils
- ✓ T-cells
- ✓ Endothelial cells



2018


Cancer hallmarks



Mechanisms of cancer-related inflammation

Main characteristic	Main pathways	Specific complications
✓ Infiltration of tumor-associated macrophages with strong immunosuppressive activity	✓ M2 macrophage phenotype ✓ Checkpoint proteins PD-1, PD-L1 and CTLA-4 ✓ IL-1beta, IL-6, TNF, IL-4, IL-10, TGF-beta ✓ Pentraxin-3	✓ T cell exhaustion and anergy ✓ Tumor progression

Highlights of onco-inflammation




1. Local and systemic dimension of inflammation

Highlights of onco-inflammation

Prognostic use of systemic inflammation

- ✓ Neutrophil count, white cell count, neutrophil/lymphocyte ratio
- ✓ Glasgow prognostic score; albumin, CRP
- ✓ B symptoms
- ✓ Circulating myeloid derived suppressor cell (MDSC) count



Highlights of onco-inflammation

2. Oncogenesis vs. oncoinflammation

OPEN ACCESS Freely available online




Molecular Profiling of Multiple Human Cancers Defines an Inflammatory Cancer-Associated Molecular Pattern and Uncovers KPNA2 as a Uniform Poor Prognostic Cancer Marker

Saleh M. Rachidi^{1,2}, Tingting Qin³, Shaoli Sun⁴, W. Jim Zheng^{3,5}, Zihai Li^{1,2*} 2013

*Gene expression data revealed an inflammatory signature shared by seven epithelial cancer types.
Oncoinflammation is a driver of oncogenesis.*

Highlights of onco-inflammation



2. Oncogenesis VS. oncoinflammation

Highlights of onco-inflammation

2. Oncogenesis vs. oncoinflammation

Leukemia (2018) 32, 438–449

OPEN

www.nature.com/leu


ORIGINAL ARTICLE

Involvement of MAF/SPP1 axis in the development of bone marrow fibrosis in PMF patients

S Ruberti^{1,10}, E Bianchi^{1,10}, P Guglielmelli², S Rontautoli¹, G Barbieri¹, L Tavernari¹, T Fanelli², R Norfo^{1,3}, V Pennucci¹, G Corbizi Fattori^{2,4}, C Mannarelli^{2,4}, N Bartalucci², B Mora⁵, L Elli⁵, MA Avanzini⁶, C Rossi¹, S Salmoiraghi⁷, R Zini¹, S Salati¹, Z Prudente¹, V Rosti⁸, F Passamonti⁵, A Rambaldi⁷, S Ferrari⁹, E Tagliafico⁹, AM Vannucchi^{2,11}, R Manfredini^{1,11} on behalf of the AGIMM (AIRC Gruppo Italiano Malattie Mieloproliferative) Investigators

Highlights of onco-inflammation

3. Age/inflammation determine the fate of HSCs



Highlights of onco-inflammation

3. Age/inflammation determine the fate of HSCs

Leukemia Research 60 (2017) 18–23



Contents lists available at ScienceDirect

Leukemia Research

journal homepage: www.elsevier.com/locate/leukres





Research paper


Primary myelofibrosis: Older age and high *JAK2V617F* allele burden are associated with elevated plasma high-sensitivity C-reactive protein levels and a phenotype of progressive disease


Giovanni Barosi^{a,*}, Margherita Massa^b, Rita Campanelli^a, Gabriela Fois^a, Paolo Catarsi^a, Gianluca Viarengo^c, Laura Villani^a, Valentina Poletto^a, Tiziana Bosoni^d, Umberto Magrini^a, Robert P. Gale^e, Vittorio Rosti^a















Fig.2

